{"title":"作为潜在抗疟候选药物的氟化哌嗪-羟乙基胺类似物的合成与评估。","authors":"Charu Upadhyay, Shreya Bhattacharya, Sumit Kumar, Kapil Vashisht, Xujie Zhang, Dominic Gagnon, Pooja Singh, Peng Zhan, Dave Richard, Brijesh Rathi, Agam Prasad Singh, Priyamvada Singh","doi":"10.1002/cmdc.202400616","DOIUrl":null,"url":null,"abstract":"<p><p>In this manuscript, twenty-one novel fluorinated piperazine-hydroxyethylamine analogues were synthesized and tested against Plasmodium falciparum (Pf). Among tested compounds, two 13 g and 14 g exhibited promising inhibitory activity on Pf3D7 with IC<sub>50</sub> values of 0.28 and 0.09 μM, respectively. Neither of the hits exhibited cytotoxicity on HepG2 cells up to 150 μM and Vero cells up to 20 μM. Compounds 13 g and 14 g were also evaluated against chloroquine-resistant PfDd2 and displayed IC<sub>50</sub> values of 0.11 and 0.10 μM, respectively. Next, 13 g and 14 g were administered to the Plasmodium berghei mice model at 30 mg/kg intraperitoneally for four consecutive doses, which showed 25 % and 50 % reduction in the parasitemia load, respectively. The efficacy of hits 13 g and 14 g was improved along with mean survival time when administered in combination with artesunate. On liver-stage parasites, compounds 13 g and 14 g showed >80 % inhibition at 1 μM. Compound 14 g was also tested for toxicity in mice at 100 mg/kg dose, which revealed no abnormality in mice organs. Preliminary pharmacokinetic studies of compound 14 g exhibited absorption and maintained a presence in the body for more than six hours.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202400616"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and Evaluation of Fluorinated Piperazine-Hydroxyethylamine Analogues as Potential Antiplasmodial Candidates.\",\"authors\":\"Charu Upadhyay, Shreya Bhattacharya, Sumit Kumar, Kapil Vashisht, Xujie Zhang, Dominic Gagnon, Pooja Singh, Peng Zhan, Dave Richard, Brijesh Rathi, Agam Prasad Singh, Priyamvada Singh\",\"doi\":\"10.1002/cmdc.202400616\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this manuscript, twenty-one novel fluorinated piperazine-hydroxyethylamine analogues were synthesized and tested against Plasmodium falciparum (Pf). Among tested compounds, two 13 g and 14 g exhibited promising inhibitory activity on Pf3D7 with IC<sub>50</sub> values of 0.28 and 0.09 μM, respectively. Neither of the hits exhibited cytotoxicity on HepG2 cells up to 150 μM and Vero cells up to 20 μM. Compounds 13 g and 14 g were also evaluated against chloroquine-resistant PfDd2 and displayed IC<sub>50</sub> values of 0.11 and 0.10 μM, respectively. Next, 13 g and 14 g were administered to the Plasmodium berghei mice model at 30 mg/kg intraperitoneally for four consecutive doses, which showed 25 % and 50 % reduction in the parasitemia load, respectively. The efficacy of hits 13 g and 14 g was improved along with mean survival time when administered in combination with artesunate. On liver-stage parasites, compounds 13 g and 14 g showed >80 % inhibition at 1 μM. Compound 14 g was also tested for toxicity in mice at 100 mg/kg dose, which revealed no abnormality in mice organs. Preliminary pharmacokinetic studies of compound 14 g exhibited absorption and maintained a presence in the body for more than six hours.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\" \",\"pages\":\"e202400616\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cmdc.202400616\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202400616","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Synthesis and Evaluation of Fluorinated Piperazine-Hydroxyethylamine Analogues as Potential Antiplasmodial Candidates.
In this manuscript, twenty-one novel fluorinated piperazine-hydroxyethylamine analogues were synthesized and tested against Plasmodium falciparum (Pf). Among tested compounds, two 13 g and 14 g exhibited promising inhibitory activity on Pf3D7 with IC50 values of 0.28 and 0.09 μM, respectively. Neither of the hits exhibited cytotoxicity on HepG2 cells up to 150 μM and Vero cells up to 20 μM. Compounds 13 g and 14 g were also evaluated against chloroquine-resistant PfDd2 and displayed IC50 values of 0.11 and 0.10 μM, respectively. Next, 13 g and 14 g were administered to the Plasmodium berghei mice model at 30 mg/kg intraperitoneally for four consecutive doses, which showed 25 % and 50 % reduction in the parasitemia load, respectively. The efficacy of hits 13 g and 14 g was improved along with mean survival time when administered in combination with artesunate. On liver-stage parasites, compounds 13 g and 14 g showed >80 % inhibition at 1 μM. Compound 14 g was also tested for toxicity in mice at 100 mg/kg dose, which revealed no abnormality in mice organs. Preliminary pharmacokinetic studies of compound 14 g exhibited absorption and maintained a presence in the body for more than six hours.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.